论文部分内容阅读
作者对24例肺癌和14例肺内感染病人的凝血酶、抗凝血酶Ⅲ复合体(TAT)及纤维蛋白溶解酶、α_2纤维蛋白溶解酶抑制物复合体(PIC)进行对照研究,探讨肺癌病期及治疗过程中TAT、PIC的变化特点。研究对象根据厚生省诊断标准选择除外DIC的病人;肺癌中男18例,女6例;年龄65.45±11.8岁;腺癌18例,Ⅰ期1例,Ⅱ期1例,Ⅲ期(ⅢA和ⅢB)5例,Ⅳ期11例;鳞癌3例,Ⅰ期2例,Ⅲ期1例;小细胞癌3例,Ⅲ期2例,Ⅳ期1例。肺感染中男11例,女3例,年龄65.3±12.4岁;细菌性肺炎5例,肺结核9例。研究
The authors conducted a controlled study of thrombin, antithrombin III complex (TAT), fibrinolytic enzyme and α_2 fibrinolytic enzyme inhibitor complex (PIC) in 24 patients with lung cancer and 14 patients with pulmonary infection. The characteristics of changes in TAT and PIC during the course of disease and treatment. Subjects selected patients with excluding DIC according to the diagnostic criteria of the Ministry of Health and Welfare; 18 males and 6 females with lung cancer; age 65.45±11.8 years; 18 adenocarcinomas, 1 in stage I, 1 in stage II, and III (IIIA and IIIB) In 5 cases, there were 11 cases of stage IV; 3 cases of squamous cell carcinoma, 2 cases of stage I, and 1 case of stage III; 3 cases of small cell carcinoma, 2 cases of stage III, and 1 case of stage IV. There were 11 males and 3 females in the lung infection, age 65.3±12.4 years old; 5 cases of bacterial pneumonia and 9 cases of pulmonary tuberculosis. the study